Patents by Inventor Marie WOOLLEY-ROBERTS

Marie WOOLLEY-ROBERTS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230022487
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the 5 cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20230026079
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20230000789
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 5, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220387377
    Abstract: The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (?)-trans- tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (+)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (?)-trans-THC. The cannabinoid (+)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 8, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220387350
    Abstract: Cannabidivarin (CBDV) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-1,3-benzenediol. Its empirical formula is C19H26O2 and its molecular weight is 286.4 g/mol. CBDV is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBDV is an off-white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBDV preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBDV which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBDV compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBDV preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBDV treatment.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 8, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220378715
    Abstract: The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of absence epilepsy. In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 1, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220378738
    Abstract: The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (?)-trans-tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (+)-trans tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (?)-trans-THC. The cannabinoid (+)-trans-THC has been found to occur in low concentrations in particular cannabis plant strains. Furthermore, the cannabinoid can be produced by synthetic means.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 1, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220378714
    Abstract: The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of Fragile X syndrome (FXS). In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 1, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220380334
    Abstract: The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (?)-trans-tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (?)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (?)-trans-THC. The cannabinoid (?)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 1, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220265573
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.
    Type: Application
    Filed: May 13, 2022
    Publication date: August 25, 2022
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220168266
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Application
    Filed: November 17, 2021
    Publication date: June 2, 2022
    Inventors: Geoffrey GUY, Volker KNAPP ERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODIE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
  • Patent number: 11207292
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 28, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
  • Publication number: 20210205262
    Abstract: The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.
    Type: Application
    Filed: December 21, 2020
    Publication date: July 8, 2021
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO
  • Publication number: 20210052512
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 25, 2021
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODLE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
  • Patent number: 10898462
    Abstract: The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: January 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo
  • Publication number: 20210015789
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Application
    Filed: September 3, 2020
    Publication date: January 21, 2021
    Inventors: Geoffrey GUY, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
  • Publication number: 20190321307
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has It been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Application
    Filed: December 13, 2017
    Publication date: October 24, 2019
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Publication number: 20190160023
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Application
    Filed: April 11, 2017
    Publication date: May 30, 2019
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO, Joanna NEILL
  • Publication number: 20190117619
    Abstract: The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.
    Type: Application
    Filed: April 11, 2017
    Publication date: April 25, 2019
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO
  • Publication number: 20190070128
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 7, 2019
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO, Joanna NEILL